ArticleBreast cancer research and treatment2025
Preferences of patients with high-risk HR + /HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany.
Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to identify preferences of patients with high-risk hormone receptor positive/human epidermal growth factor receptor 2 negative (HR + /HER2-) early breast cancer (EBC) related to adjuvant endocrine therapy (ET) using the Adaptive Choice-Based Conjoint (ACBC) method.
methodsA stepwise multimodal study was conducted in Germany between October 2021 and March 2022 consisting of desk research, qualitative interviews, and quantitative online surveys. Included patients had a high risk of recurrence at the time of their HR + /HER2- EBC diagnosis, completed primary therapy (surgery ± radiation + (neo)adjuvant chemotherapy), and were prescribed or undertaking adjuvant ET. In the desk research phase, online resources, patient material, and existing studies were reviewed. In the qualitative phase, interviews were conducted with 6 gynaecologists, 6 oncologists, 20 patients, and 5 caretakers. In the quantitative phase, 85 patients completed the ACBC analysis survey.
resultsIncluded patients were aged 49.4 years (mean) among which 69.4% were still working. In the ACBC absolute rating, diarrhoea, arthralgia, and nausea were least relevant attributes to patients. Relative assessment of ET attributes against each other revealed that achieving the ET goal, namely the reduction of risk of tumour recurrence, had the highest relevance, while avoiding side effects and maintaining quality of life were less relevant. Overall, 35% have considered taking a break or discontinuing adjuvant ET due to side effects.
conclusionReduction of tumour recurrence was the attribute of highest relative importance for patients with high-risk HR + /HER2- EBC followed by side effect avoidance and quality-of-life maintenance, reflecting their importance in treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.